These findings may be a plausible explanation for the contradictory results regarding the predictive value of AT for VEGF-targeted treatment [15–18], and to some extent support our hypothesis that anti-angiogenic therapy in patients cancer with high adipose depots, who have preexisting AT dysfunction, is more likely to result in the reduction of inflammatory cytokines, which may favor a better outcome. This evidence concerns the gene VEGFA and cancer.